AD-GL0001
Latest Information Update: 25 May 2006
At a glance
- Originator ActinoDrug Pharmaceuticals
- Class Antirheumatics; Small molecules
- Mechanism of Action Mitogen-activated protein kinase kinase inhibitors; Tumour necrosis factor inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Rheumatoid arthritis
Most Recent Events
- 25 May 2006 No development reported - Preclinical for Rheumatoid arthritis in Germany (PO)
- 15 Jan 2003 AD-GL0001 is available for licensing (www.actinodrug.de)
- 15 Jan 2003 Preclinical trials in Rheumatoid arthritis in Germany (PO)